Dyadic International is betting that more drugmakers and food companies will switch to animal-free proteins made through fermentation, but those deals can take longer than expected to turn into steady sales. The upside hinges on partners and regulators moving faster—while the downside is ongoing cash burn and potential shareholder dilution if timelines slip.Read more
Dyadic International aims to make animal-free proteins used in medicines and new kinds of food, and early commercial sales plus new partners could shift it from one-off payments to steadier product revenue. The upside depends on customers scaling up and costs staying under control, because delays, partner bottlenecks, or tougher rules could keep losses going and force more fundraising.Read more
Dyadic International is trying to turn its enzyme and protein platform into a real product business, betting that rising demand for animal-free, sustainable ingredients will bring steadier sales through new launches and partner programs. The big question is whether it can grow fast enough to outrun ongoing losses and the risk that key partner payments or approvals arrive later than hoped.Read more
No trending discussion available.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
